1. Home
  2. XPON vs MBIO Comparison

XPON vs MBIO Comparison

Compare XPON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expion360 Inc.

XPON

Expion360 Inc.

N/A

Current Price

$2.50

Market Cap

4.1M

Sector

Technology

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.39

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XPON
MBIO
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.1M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
XPON
MBIO
Price
$2.50
$0.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.8K
★ 36.8K
Earning Date
11-16-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
94.63
★ 98.99
EPS
N/A
★ N/A
Revenue
★ $9,651,870.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$405.45
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 71.59
N/A
52 Week Low
$0.26
$0.35
52 Week High
$11.79
$1.44

Technical Indicators

Market Signals
Indicator
XPON
MBIO
Relative Strength Index (RSI) 29.06 45.60
Support Level $0.51 $0.35
Resistance Level $3.82 $0.43
Average True Range (ATR) 0.34 0.03
MACD -0.10 0.01
Stochastic Oscillator 14.21 64.93

Price Performance

Historical Comparison
XPON
MBIO

About XPON Expion360 Inc.

Expion Energy Inc is engaged in premium lithium iron phosphate (LiFePO4) batteries and accessories for recreational vehicles, marine applications, Light EV and industrial applications. The company's lithium-ion batteries feature half the weight of standard lead-acid batteries while delivering three times the power and ten times the number of charging cycles. The company's batteries also feature construction and reliability compared to other lithium-ion batteries on the market due to their superior design and quality materials.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: